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Objective: Ageing is associated with changes in cognition in some, but not all domains. In young–old
adults, deﬁned as persons aged 65–84 years, baseline cognitive function has been shown to impact on
cognitive trajectories. Whether similar patterns occur in the very-old, deﬁned as persons aged 85 years
and over, is not known.
Methods: Longitudinal changes (5 years’ follow-up) in global and domain speciﬁc cognitive function
including memory, attention and speed were investigated in participants from the Newcastle 85+ Study
(n = 845). At baseline, participants were grouped using Mini-Mental State Examination cut-off scores
and dementia status into the following: not impaired, mildly impaired or severely impaired/dementia
groups.
Results: Only a limited number of cognitive measures showed signiﬁcant decline in performance over
time. Where observed, change generally occurred only in the severely impaired group. In the severely
impaired group, small differences in baseline age were associated with poorer performance over time
on most measures. Education was not protective against cognitive decline in any group.
Conclusions: There are individuals who maintain a high level of cognitive function or only show mild
impairments even into their ninth decade of life. This group of successful cognitive agers may provide
insight for identifying predictors of cognitive integrity in later life. In individuals with severe
impairment, cognitive performance shows signiﬁcant decline over time, especially in measures of
attention and speed. Further work to identify those individuals at highest risk of cognitive decline is
necessary to implement early support and intervention strategies in this rapidly expanding age group.
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Introduction
Longitudinal studies have reported large individual
variability in cognitive performance in older aged
adults with some individuals showing a decline in
functioning, others remaining stable and some even
improving (Brayne et al., 1992; Lyketsos et al.,
1999; Howieson et al., 2003; Terrera et al., 2010).
Individual differences may be explained by
variability in resilience to the effects of ageing
through, for example, reserve or compensation,
health-related factors or learning effects. Cognitive
decline has been associated with an increased risk
of mild cognitive impairment and dementia and
can impede independence and mobility. Therefore,
in older populations, knowing which cognitive
domains change as a function of time (versus disease
processes), and the measures that are most sensitive
to detect and monitor change over time are
important not only for creating diagnostic protocols
but also for the development and testing of
personalised interventions focused on improving or
maintaining cognitive function in later life.
Exactly which cognitive domains are and are not
resilient to ageing has been extensively studied.
Generally, although not always, general knowledge
improves with age, while speed, attention, inhibition
and memory decline, and abstraction has been
found to remain stable (Goh et al., 2012). However,
whether these trends are also observed in the
very-old, deﬁned as persons aged 85 years and
older, is not known. Indeed, studies investigating
trajectories of cognitive function in older
populations have largely been derived from samples
of young–old persons (e.g. 65–84 years) or samples
with very broad age ranges (e.g. from mid to later
life). As such, they may not be representative of
the very-old population who are a unique survivor
cohort. Further, the very-old are the most rapidly
growing age segment of the population and have
the highest risk of cognitive decline and dementia
(Kinsella and He, 2009). Individuals aged 85 years
and over may have greater sensory (e.g. vision
and hearing) and physical impairment, and
comorbidities that may inﬂuence cognitive
performance (Collerton et al., 2009; Jefferis et al.,
2013). They may also form a select cohort
characterised by a more protective biological proﬁle
and have better health or lifestyles that increase
resilience. Each of these factors could modify
cognitive trajectories in this age group (Ankri and
Poupard, 2003; Slavin et al., 2013). Thus, while
research suggests that cognitive impairment is
common in very-old age, it may not necessarily be
inevitable (Kliegel et al., 2004).
In this study, we investigated, for the ﬁrst time,
cognitive trajectories of global and domain speciﬁc
functioning including memory, attention and speed,
in a cognitively diverse sample of individuals aged
85 years at baseline. As baseline functioning has been
found to impact cognitive trajectories in young–old
samples (de Frias et al., 2009; Mungas et al., 2010),
we investigated longitudinal changes in groups deﬁned
using baseline Mini-Mental State Examination
(MMSE) cut-off scores and dementia status with
individuals classiﬁed into the following: not impaired
(MMSE 26–30), mildly impaired (MMSE 22–25) or
severely impaired/dementia (MMSE ≤21 or dementia
diagnosis) groups.
Methods
Participants
Data are from the Newcastle 85+ Study and full
details have been published (Collerton et al., 2007;
Collerton et al., 2009). In brief, the sampling frame
comprised all people born in 1921, aged 85 years
in 2006 when recruitment commenced, who were
registered with a participating general practice (GP)
in Newcastle upon Tyne in the north-east of
England. All individuals who meet these inclusion
criteria were invited to participate, whether living
at home or in an institution and regardless of their
health status (except for exclusion by their general
practitioner due to end stage terminal illness). In
total, 1459 individuals were invited to participate
and 358 (24.5%) declined (Collerton et al., 2009).
Recruitment and baseline assessment took place over
a 17-month period beginning in 2006. Of the 1042
people recruited, 845 agreed to a health assessment
and a review of their GP records. These individuals
form the basis of our analytical sample. Participants
were re-seen at 18 (phase 1), 36 (phase 2) and 60
(phase 3) months.
The Newcastle 85+ Study sample is broadly
representative of the local population (Collerton
et al., 2009). To investigate whether differential
response might affect the results, comparison
between the refusers and those agreeing to the
health assessment and record review found that
the groups did not signiﬁcantly differ in terms of
deprivation but there was underrepresentation of
females in those who agreed to participate
(Collerton et al., 2009).
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Ethics
The Newcastle and North Tyneside 1 Research Ethics
Committee approved the study. Informed written
consent was obtained from all participants or their
consultee (usually a relative) where capacity to consent
was assessed as lacking for example because of severe
cognitive impairment or dementia.
Interview
At baseline, a detailed multi-dimensional health
assessment, including questionnaires, measurements
(e.g. blood pressure), functional and cognitive tests,
was completed and a fasting blood sample collected.
A trained research nurse conducted the health
assessment in the participant’s usual place of
residence. The research nurse team also undertook a
review of each participants’ GP clinical records.
Participants could decline elements of the protocol,
and this did not constitute exclusion. At follow-up,
repeat measures of core variables were collected
including health, cognition and physical function.
For analysis, we extracted socio-demographic
information including age, sex, years of education
and place of residence (institutionalised versus non-
institutionalised). Health status including pre-existing
hypertension, cerebrovascular disease (i.e. stroke or
transient ischaemic attack or carotid endarterectomy),
diabetes (including medication for diabetes in the
absence of diagnosis), ischaemic heart disease (IHD;
angina or myocardial infarction or coronary artery
bypass grafts or coronary angioplasty or coronary
stent), peripheral vascular disease (PVD) and
dementia was collected from the review of GP records
(Collerton et al., 2009). Disability was assessed based
on self-reported ability to perform instrumental and
basic activities of daily living (Kempen et al., 1996;
Jagger, et al., 2011). The disability scale was formed
by the sum of the number of items where a participant
reported difﬁculty and scores were categorised into
four groups: disability free (0), mild (1–6), moderate
(7–12) and severe (13+) disability.
Cognitive measures
Global cognitive function was assessed using the
MMSE (Folstein et al., 1975; Molloy and Standish,
1997). MMSE scores range from 0 to 30. The MMSE
was administered at baseline, 36 and 60 months.
Speed, attention and episodic memory were assessed
using the Cognitive Drug Research (CDR)
computerised system (Simpson et al., 1991; Ballard
et al., 2002; Wesnes et al., 2005; Wesnes, 2008).
The CDR was presented on a hi-resolution
Windows-based tablet computer with a two-button
(yes/no) response box. Administration of the CDR
battery was completed in two stages. A training session
was performed to familiarise participants with the
computerised testing procedures, using all selected
tasks but with fewer stimuli. Approximately 1 week
later the assessment data were collected. CDR tasks,
in order of administration, included word
presentation, simple reaction time, digit vigilance
task, choice reaction time and word recognition
(Simpson et al., 1991). A description of each task
is available in Table S1. The scores from these
tasks were combined to calculate ﬁve composite
measures: power of attention (PoA; a measure of
focused attention, measured in milliseconds),
Continuity of Attention (CoA; a measure of
sustained attention or vigilance over time, measured
as a trade-off between correct responses and false
alarms), response variability (ResV; a measure of
ﬂuctuations in attention, measured as a coefﬁcient
of variation) and the word recognition accuracy
sensitivity index score (a measure of memory,
calculated from the formula presented by Frey
and Colliver (Frey and Colliver, 1973) that
combines the ability to recognise target stimuli with
the ability to correctly reject distractors; range 1
to 1). Reaction times (milliseconds) for each of
the three attention tasks (simple reaction time,
choice reaction time and digit vigilance reaction
time) and word recognition speed were also
selected for analysis. All reaction time scores were
converted to seconds for analysis. The CDR battery
was administered at baseline, 18 and 36 months.
For all attention (except CoA) and the speed
measures, lower scores indicate better performance.
For the MMSE and the memory task (sensitivity
index), higher scores indicate better performance.
Analysis
Using baseline MMSE scores, individuals were
categorised into not impaired (26–30), mildly
impaired (22–25) or severely impaired (MMSE ≤ 21)
groups. All individuals with a diagnosis of dementia
at baseline (n = 74, 8.8%) were also grouped into the
severely impaired category. Group differences in
baseline demographic, lifestyle, health and cognitive
variables were compared using the χ2 statistic for
categorical variables or analysis of variance (or
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Kruskal–Wallis test for non-normally distributed
variables) for continuous variables.
Trajectories of cognitive change were modelled
using repeated-measures mixed-effects linear models
independently for each cognitive group. Because
there were only up to three measures per person for
each cognitive test, a model describing change as
occurring at a constant rate over the entire follow-
up time was ﬁtted. Mixed models were estimated
using maximum likelihood estimation, and estimates
were robust under a missing at random assumption.
All models were adjusted for sex (0 = male,
1 = female), years of education (centred at 7 years,
the average number of years of education in the
sample) and age at study entry (centred at age 85; this
was performed because of small age differences at
baseline with age ranging from 84.5–86.6 years, as
recruitment took place over a 17-month period).
Given that cerebrovascular disease status differed
across the groups, a sensitivity analysis was
undertaken by including this variable as a covariate
in the models. The pattern of associations was
unchanged (data not shown). Analyses were
completed using STATA version 14.
Results
Demographic and baseline cognitive test scores
Of the 845 participants included in the analysis, most
(69.8%, n = 590) were classiﬁed as not cognitively
impaired, while 14.8% (n = 125) and 15.4% (n = 130)
were classiﬁed as mildly and severely impaired,
respectively. Table 1 shows the baseline characteristics,
health status and distribution of the baseline MMSE
and CDR scores for each group. There were no signiﬁcant
differences in age at baseline, gender, educational
attainment and prevalence of hypertension, diabetes,
PVD or IHD by cognitive group. In contrast, the severely
impaired group had a higher rate of institutionalisation,
greater level of disability, higher prevalence of
cerebrovascular disease and poorer baseline performance
on all cognitive (i.e. MMSE and CDR) measures.
Missing
Table 2 shows the pattern of missing data for each
cognitive score for the total sample and by cognitive
Table 1 Sample demographics and baseline cognitive test scores by cognitive group
Not impaired (N = 590) Mildly impaired (N = 125) Severely impaired (N = 130) p-valuea
Demographics
Baseline age mean (SD) 85.5 (0.4) 85.4 (0.4) 85.5 (0.5) 0.214b
Female % (n) 61.9 (365) 57.6 (72) 68.5 (89) 0.190
Education mean (SD), years 10.0 (1.9) 9.7 (1.7) 9.8 (1.9) 0.199b
Institutionalised % (n) 0.9 (5) 11.2 (14) 51.4 (67) <0.001
Health
Hypertension % (n) 59.3 (350) 56.0 (70) 49.2 (64) 0.104
Peripheral vascular disease % (n) 6.8 (40) 8.0 (10) 6.9 (9) 0.888
Ischaemic heart disease % (n) 32.4 (191) 39.2 (49) 29.2 (38) 0.211
Cerebrovascular disease % (n) 17.8 (105) 28.0 (35) 29.2 (38) 0.002
Diabetes % (n) 13.2 (78) 12.8 (16) 13.9 (18) 0.969
Dementia % (n) N/A N/A 56.9 (74) N/A
Disability score
0 (disability free) % (n) 24.6 (145) 12.8 (16) 2.3 (3) <0.001
1–6% (n) 56.4 (333) 47.2 (59) 28.5 (37)
7–12% (n) 15.3 (90) 26.4 (33) 33.1 (43)
13 or more % (n) 3.7 (22) 13.6 (17) 36.2 (47)
Median cognitive test scores (IQR)c
Mini-Mental State Examination 29 (27, 29) 24 (23, 25) 19 (11, 21) <0.001
Memory: sensitivity index 0.6 (0.5, 0.7) 0.5 (0.3, 0.7) 0.3 (0.1, 0.5) <0.001
Power of attention, s 1.5 (1.3, 1.6) 1.7 (1.5, 1.8) 1.9 (1.6, 2.3) <0.001
Continuity of attention, # 55 (52, 57) 52 (45, 57) 46 (33, 53) <0.001
Response variability 58.1 (50.7, 67.7) 64.0 (56.7, 78.9) 71.0 (59.5, 99.3) <0.001
Simple reaction time, s 0.4 (0.3, 0.4) 0.5 (0.4, 0.6) 0.5 (0.4, 0.8) <0.001
Choice reaction time, s 0.6 (0.5, 0.6) 0.6 (0.6, 0.7) 0.8 (0.6, 1.0) <0.001
Digit vigilance reaction time, s 0.5 (0.5, 0.5) 0.5 (0.5, 0.6) 0.6 (0.5, 0.6) <0.001
Word recognition speed, s 1.3 (1.0, 1.6) 1.6 (1.2, 2.1) 2.3 (1.5, 3.5) <0.001
Key # number; IQR, interquartile range; s, seconds; SD, standard deviation.
aChi-squared, unless stated otherwise.
bAnalysis of variables (ANOVA).
cDifferences between groups tested using the Kruskal-Wallis test.
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group. The majority of loss to follow-up occurred
between baseline and the ﬁrst follow-up interview. Loss
to follow-up over time was greatest in the severely
impaired group. When comparing individuals with only
bassline MMSE scores (n = 361) to those with one or
more MMSE follow-up assessments (n = 478), we found
no differences in baseline age (p = 0.67), gender
(p = 0.42) or disease status including hypertension
(p = 0.96), IHD (30.33 vs 36.84, p = 0.05) and diabetes
(p = 0.44) between the two groups. However, those
who were seen at follow-up had higher educational
attainment (mean = 10.06 (SD = 1.98) versus
mean = 9.72 (SD = 1.67), p = 0.008) and baseline MMSE
scores (mean = 27.13 (SD = 3.25) versus mean = 24.17
(SD = 6.88), p < 0.001), were less likely to be living in
an institution (3.14% vs 18.3%, p < 0.001) and have
PVD (5.23% vs 9.42%, p = 0.019), cerebrovascular
disease (18.00 vs 24.93, p = 0.020), dementia (3.77 vs
13.85, p < 0.001) and disability (severe disability 3.77%
vs 18.01%, p < 0.001), compared with the group seen
only at baseline.
Longitudinal changes in cognitive function
Table S2 shows the results from the mixed-effects
linear regression analyses for measures of global
cognitive function, memory, attention and speed
when controlling for age, sex and years of education.
Figure 1 shows the trajectories of test scores on each
measure for the three cognitive groups over the
5-years follow-up.
Global cognitive function
Over time, there was a signiﬁcant decline in MMSE
scores in the not impaired group (B =0.48, SE = 0.15,
p < 0.005); age, sex and education were not risk
factors for the rate of change. In the mildly impaired
group, MMSE scores did not change over time. In
contrast, in the severely impaired group, higher
baseline age was associated with poorer performance
over time (B = 1.67; SE = 0.8, p = 0.035).
Memory: sensitivity index
Memory changed signiﬁcantly only in the severely
impaired group where higher baseline age was
associated with poorer performance over time
(B = 0.10; SE = 0.05, p = 0.042).
Attention
In both the not impaired and mildly impaired groups,
focused attention (i.e. PoA) scores did not change over
time. In contrast, in the severely impaired group,
performance declined signiﬁcantly over time
(B = 0.63; SE = 0.23, p = 0.005) and the rate of change
differed by sex with slower rates of decline in women
(B = 0.41; SE = 0.19, p = 0.033). Sustained attention
(i.e. CoA) and response variability (i.e. ResV) scores
remained stable over time in all groups.
Table 2 Number of people (%) with data on each cognitive variable (MMSE and CDR scores) at each follow-up (FU) interview for the total sample
and stratiﬁed by cognitive group
Total sample Not impaired Mildly impaired Severely impaired
T0 FU1* FU2** T0 FU1* FU2** T0 FU1* FU2** T0 FU1* FU2**
MMSE 839 470 (56.0) 331 (70.4) 590 369 (62.5) 273 (74.0) 125 67 (53.6) 43 (64.2) 124 34 (27.4) 15 (44.1)
Memory 753 563 (74.8) 412 (73.2) 568 447 (78.7) 344 (77.0) 103 73 (70.9) 51 (69.9) 82 43 (52.4) 17 (39.5)
PoA 753 562 (74.6) 415 (73.8) 567 447 (78.8) 346 (77.4) 104 72 (69.2) 52 (72.2) 82 43 (52.4) 17 (39.5)
CoA 753 562 (74.6) 415 (73.8) 568 447 (78.7) 346 (77.4) 103 72 (69.9) 52 (72.2) 82 43 (52.4) 17 (39.5)
ResV 752 562 (74.7) 413 (73.5) 567 447 (78.8) 345 (77.2) 104 72 (69.2) 52 (72.2) 81 43 (53.1) 16 (37.2)
SRT 761 570 (74.9) 416 (73.0) 569 452 (79.4) 347 (76.8) 104 74 (71.2) 52 (70.3) 88 44 (50.0) 17 (38.6)
CRT 757 567 (74.9) 415 (73.2) 568 450 (79.2) 346 (76.9) 104 73 (41.3) 52 (71.2) 85 44 (51.8) 17 (38.6)
DVRT 756 563 (74.5) 416 (73.9) 568 447 (78.7) 347 (77.6) 104 73 (70.2) 52 (71.2) 84 43 (51.2) 17 (39.5)
WRS 753 563 (74.8) 412 (73.2) 568 447 (78.7) 344 (77.0) 103 73 (70.9) 51 (69.9) 82 43 (52.4) 17 (39.5)
Key: T0, time 0 (baseline, phase 1); CoA, continuity of attention; CRT, choice reaction time; DVRT, digit vigilance reaction time; MMSE, Mini-
Mental State Examination; PoA, power of attention; ResV, response variability; SRT, simple reaction time; WRS, word recognition speed.
The CDR and MMSE were administered at different time points such that
*FU1 = follow-up 1 (phase 3 for MMSE and phase 2 for CDR measures) and
**FU2 = follow-up 2 (phase 4 for MMSE and phase 3 for CDR measures).
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Speed: reaction time scores
Results varied across the different speed measures. For
simple reaction time scores, only the severely impaired
group showed a signiﬁcant slowing in performance
over time (B = 0.36 SE = 0.14, p = 0.012). Choice
reaction time scores remained stable over time in all
groups. For digit vigilance reaction time, performance
declined signiﬁcantly over time in the not impaired
group (B = 0.01; SE = 0.00, p < 0.001), and in the
severely impaired group, higher baseline age was
associated with a signiﬁcant decline in performance
over time (B = 0.04; SE = 0.02, p = 0.038).
Discussion
In this study, we examined the trajectories of cognitive
performance on measures of global cognitive function,
memory, attention and speed in different groups of
very-old individuals deﬁned by MMSE scores and
dementia status. The results highlight that groups
who were not impaired or mildly impaired at age
85 years had relatively stable performance across most
measures, even into their 90th year of life. In contrast,
we found decline in the severely impaired group (with
the exception of MMSE and digit vigilance reaction
times scores that declined signiﬁcantly in the not
impaired group) but not on all measures. Further, in
the severely impaired group, very small differences in
baseline age appeared to result in poorer performance
over time on measures of global cognitive function,
memory and speed (digit vigilance task only).
Education did not appear to signiﬁcantly impact the
rate of change in any group, and gender differences
were rarely observed. The results have implications
for the development and targeting of cognitive-
focused intervention strategies for very-old individuals
including strategies aimed at maintaining cognitive
integrity in high functioning groups and improving
cognition, particularly in the domains of speed and
attention, in already impaired individuals. They also
highlight that cognitive decline is not an inevitable
consequence of advanced ageing and that many very-
old individuals can maintain a high level of cognitive
function.
Cognitive change between ages 85 and 90 years
Not and mildly impaired groups. In the not impaired
group, global cognitive function declined over time
Figure 1 Pattern of changes in MMSE and CDR (memory, attention and speed) scores for each cognitive group over the 5-year follow-up.
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(less than half a point change on the MMSE per year)
and digit vigilance speed became slower. In contrast,
in the mildly impaired group, cognitive performance
remained stable on all measures. Taken together, these
results suggest that in the very-old population,
deﬁning not impaired or mildly impaired groups
according to MMSE cut-off scores captures
individuals with relatively stable or only slowly
changing cognitive function over time. Impairment
captured in the mildly impaired group in this
population therefore appears to be associated with
non-pathological changes given that there is little risk
of decline even into advanced older age.
Severely impaired group. In the severely impaired
group, while global cognitive function, sustained
attention and speed (choice reaction time) remained
stable over the 5-year follow-up, focused attention
declined and speed on the simple reaction time task
became slower. Covariates inﬂuenced longitudinal
performance with higher baseline age associated with
poorer global cognitive function, memory and
reaction time on the digit vigilance task and being
male a risk factor for poorer focused attention. Taken
together, these ﬁndings suggest that the CDR
measures of sustained attention and a simple speed
task, rather than memory or the MMSE, are sensitive
to capturing change in individuals with severe
cognitive impairment/dementia. This supports
ﬁndings of the usefulness of the CDR in tracking
cognitive change in clinical samples with dementia
(McKeith et al., 2000; Emre et al., 2004; Wesnes
et al., 2010) and extends them to individuals aged 85
+ years in a population setting. Future work will
determine why some domains and not others show
decline over time in the severely impaired group
including an in-depth investigation of the association
between cognition and health, lifestyle and reserve
factors.
Surprisingly, education was not found to be
associated with rate of change on any cognitive
measure across the different groups. This is in line
with previous null ﬁndings (Piccinin et al., 2013).
Generally, in longitudinal studies, education is found
to be associated with the intercept, not the slope, as
reported here. In contrast, in cross-sectional studies
and for dementia risk, education is typically found to
be protective. Indeed, in both the 90+ Study and
WISE, lower educational attainment was found to be
associated with an increased risk of dementia in the
very-old. Therefore, further work exploring reasons
behind the results and investigating the link between
educational attainment and other proxies of reserve
(i.e. occupational level and engagement in mentally
stimulating activities) and risk of dementia in the
Newcastle 85+ Study is needed to better determine
the role of education on cognitive function in this
age group.
Strengths and limitations. There are a number of
strengths to this study. The Newcastle 85+ Study is a
large population-based cohort of the very-old, socio-
demographically representative of this age group in
the UK, including individuals in institutions
(Collerton et al., 2009). Home-based assessments were
undertaken that helps to avoid selection bias inherent
in clinic-based assessment of this age group. In
addition, relatively long follow-up has been
undertaken (5 years) with little loss to follow-up apart
from death (Davies et al., 2010). The cognitive battery
incorporated a wide variety of tests including
measures of global and domain speciﬁc cognitive
function: memory, attention and speed. There are
some limitations. First, not all cognitive measures
were administered at every follow-up wave because
of time restrictions. Second, as with any study of
ageing, follow-up is associated with loss, mainly due
to death, and when looking at attrition rates across
groups, this was especially evident in the severely
impaired group. Further, loss to follow-up was found
to be associated with lower educational attainment,
poor functional, cognitive and health status. This
differential loss could affect generalisability of the
results. However, we used mixed-effects regression
that controls for time in addition to bias resulting
from incomplete observations. Last, given that each
cognitive measure (MMSE and CDR) was
administered at three time points, only linear change
could be modelled.
Conclusion
In the very-old, cognitive function generally remained
stable over time in not impaired and mildly impaired
groups but did decline signiﬁcantly, especially in
measures of attention and speed, once a threshold is
met (e.g. an individual is severely impaired/has
dementia). Education was not protective against rate
of decline. Poorer performance was associated with
increasing age for some but not all measures at
follow-up in the severely impaired group, whilst
gender differences were not consistently observed.
Further research is needed to identify risk factors for
cognitive decline in the different cognitive groups
and to develop strategies to improve cognitive
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function or prevent further impairment in individuals
with severe impairments. This is particularly
important as lifespan continues to increase and the
ageing population expands.
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Key points
• In the very-old (i.e. persons ≥85 years),
cognitive function remains relatively stable
over time in not impaired and mild cognitively
impaired groups, but declines, especially on
measures of attention and speed, in individuals
with severe impairment/dementia.
• Cognitive decline is not an inevitable
consequence of advanced ageing; many very-
old individuals can maintain high cognitive
function into their 90th year of life.
• Determining factors that promote successful
cognitive functioning in advanced old age will
have important implications for developing
strategies to prevent cognitive decline in this
age group.
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